Please assess the completion status of the following clinical trial:

Trial Title: Cell-Free DNA and RNA in Blood fromMetastatic Prostate Cancer Patients

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* A diagnosis of histologically confirmed prostate adenocarcinoma and falling into one of the following 5 groups:~  * Currently receiving ADT (previously untreated for metastatic disease)~    * These patients will be grouped into 3 cohorts: having received ADT for 3-6 months; for 1-2 years; and for \> 3 years~ * Scheduled to begin treatment with ADT (previously untreated for metastatic disease)~ * Scheduled to begin treatment with enzalutamide (castration resistant / has received ADT / may have received abiraterone)~ * Scheduled to begin treatment with abiraterone (castration resistant / has received ADT / may have received enzalutamide)~ * Scheduled to begin treatment with docetaxel (castration resistant / has received ADT / has received enzalutamide and/or abiraterone)~* Have been diagnosed with either hormone-naive or castrate-resistant metastatic disease~* Ability and willingness to provide written and informed consent~Exclusion Criteria:~* Patients who receive combined ADT with docetaxel for hormone-naive metastatic prostate cancer~* Patients on intermittent ADT

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ancillary-Correlative (blood collection) (Type: None): Patients undergo blood collection every 4-12 weeks during ADT, abiraterone, enzalutamide, or docetaxel treatment. Patients switched from ADT to either abiraterone or enzalutamide during the study will undergo phlebotomy every 6-12 weeks. Samples are analyzed for cfRNA, and cfDNA, AR-V7, and other AR-Vs via quantitative RT-PCR.

Based on this trial design, predict the completion outcome and termination type (if applicable).